Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 915-926

  Baker, Sharyn D ^a   Diasio, Robert B ^a   O'Reilly, Seamus ^a   Lucas, V Sol ^a   Khor, Soo Peang ^a   Sartorius, Susan E ^a   Donehower, Ross C ^a   Grochow, Louise B ^a   Spector, Thomas ^a   Hohneker, John A ^a   Rowinsky, Eric K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033975358     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.915     Document Type: Article

References (37)

1. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs - Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
2. de Takats PG, Kerr DJ, Poole CJ, et al: Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer 69:372-378, 1994
3. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study [see comments]. J Clin Oncol 13:1303-1311, 1995
4. Rougier P, Buyse M, Ryan L, et al: Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:267a, 1997 (abstr 946)
5. Spector T, Cao S, Rustum YM, et al: Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 55:1239-1241, 1995
6. Okeda R, Shibutani M, Matsuo T, et al: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol (Berl) 81:66-73, 1990
7. Zhang RW, Soong SJ, Liu TP, et al: Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats: Potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab Dispos 20:113-119, 1992
8. Naguib FN, el Kouni MH, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985
9. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
10. Fleming RA, Milano GA, Gaspard MH, et al: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 5:740-744, 1993
11. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438, 1993
12. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
13. Lu Z, Zhang R, Carpenter JT, et al: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4:325-329, 1998
14. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992
15. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients [see comments]. J Clin Oncol 12:2248-2253, 1994
16. Porter DJ, Chestnut WG, Merrill BM, et al: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 267:5236-5242, 1992
17. Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
18. Baccanari DP, Davis ST, Knick VC, et al: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A 90:11064-11068, 1993
19. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996
20. Schilsky RL, Hohneker J, Ratain MJ, et al: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450-1457, 1998
21. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
22. Arellano M, Malet-Martino M, Martino R, et al: 5-Ethynyluracil (GW776): Effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Br J Cancer 76:1170-1180, 1997
23. 19F nuclear magnetic resonance spectroscopy. Cancer Res 59:122-127, 1999
24. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
25. Harris BE, Song R, Soong SJ, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
26. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
27. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982
28. Grem JL: 5-Fluoropyrimidines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott Raven, 1996, pp 149-217
29. Yoshida T, Araki E, Iigo M, et al: Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26:352-354, 1990
30. Grem JL, McAtee N, Balis F, et al: A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72:663-668, 1993
31. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 81:47-51, 1988
32. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249, 1985
33. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991
34. Takimoto CH, Lu ZH, Zhang R, et al: Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2:477-481, 1996
35. Shiotani T, Weber G: Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 256:219-224, 1981
36. Spector T, Porter DJT, Nelson J, et al: 5-ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 19:565-571, 1994
37. Mani S, Beck T, Chevlen E, et al: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:281a, 1998 (abstr 1083)